Clinical trials: Pharmacokinetics of ASP9853
Pharmacokinetics of ASP9853, Non-hematologic Malignancies
A Phase 1, Dose Escalation Study to Assess the Safety and Tolerability of ASP9853 With Either Docetaxel or Paclitaxel in Patients With Advanced Non-hematologic Malignancies
The purpose of this study is to determine the safety and tolerability and pharmacokinetics of ASP9853 combined with docetaxel or with paclitaxel in subjects with advanced non-hematologic malignancies.
- Trial name
- NCT01705483
- Testing
- ASP9853, Docetaxel, Paclitaxel
- Where
- 4 sites in United States
- Volunteers
- 21 people
- Sponsor
- Astellas Pharma Global Development, Inc.